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AbstrAct
Purpose This is a retrospective cohort study using 
observational data from anonymised primary care records. 
We identify and extract all patients with type 2 diabetes 
and associated clinical data from the Clinical Practice 
Research Datalink (CPRD) to inform models of disease 
progression and stratification of treatment.
Participants Data were extracted from CPRD on 8 
August 2016. The initial data set contained all patients 
(n=313 485) in the database who had received a type 2 
diabetes medication. Criteria were applied to identify and 
exclude those with type 1 diabetes, polycystic ovarian 
syndrome or other forms of diabetes (n=40 204), and for 
data quality control (n=12). We identified 251 338 patients 
for inclusion in future analyses of diabetes progression and 
treatment response.
Findings to date For 6-month response to treatment, 
measured by change in glycated haemoglobin (HbA1c), 
we have 91 765 patients with 119 785 treatment 
response episodes. The greatest impact on reduction of 
HbA1c occurs with first-line and second-line treatments, 
metformin and sulfonylurea. Patients moving to third-
line treatments tend to have greater weights and higher 
body mass index. We have investigated the impact of 
non-adherence to commonly used glucose-lowering 
medications on HbA1c. For baseline-adjusted HbA1c 
change over 1 year, non-adherent patients had lower 
HbA1c reductions than adherent patients, with mean and 
95% CI of −4.4 (−4.7 to −4.0) mmol/mol (−0.40 (−0.43 to 
−0.37) %).
Future plans Findings from studies using these data 
will help inform future treatment plans and guidelines. 
Additional data are added with updates from CPRD. 
This will increase the numbers of patients on newer 
medications and add more data on those already receiving 
treatment. There are several ongoing studies investigating 
different hypotheses regarding differential response to 
treatment and progression of diabetes. For side effects, 
links to Hospital Episode Statistics data, where severe 
events such as hypoglycaemia will be recorded, will also 
be explored.
IntroductIon
Understanding the clinical factors that are 
associated with response to glucose-lowering 
therapy in type 2 diabetes could form the 
basis of selecting subgroups of patients who 
are most suited to a specific treatment, an 
approach known as ‘stratified’ or ‘precision’ 
medicine. Type 2 diabetes is an area of medi-
cine where a stratified approach to treatment 
may be of particular interest because there 
are differences in the underlying pathophysi-
ology between patients, marked variations in 
drug response and diabetes progression, and 
a number of different glucose-lowering ther-
apies with different mechanisms of action. 
Newly diagnosed patients with type 2 diabetes 
are usually prescribed metformin as a first 
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Cohort profile
strengths and limitations of this study
 ► Different treatments for type  2 diabetes have 
different mechanisms of action. At present it is 
unknown which patients will respond best to a 
particular therapy.
 ► The Clinical Practice Research Datalink (CPRD) 
is the largest validated primary care longitudinal 
health record database in the world and a potentially 
valuable resource to investigate individual response 
to treatment in patients with type 2 diabetes.
 ► This protocol details a method for extracting and 
cleaning data relating to therapy and biomarkers for 
studies of type 2 diabetes using CPRD.
 ► Data from the study can inform models of disease 
progression and response to therapy.
 ► There are small patient numbers on newer 
treatments, such as sodium-glucose co-
transporter-2  (SGLT2) inhibitors; however, as the 
study is ongoing, these will increase.
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Figure 1 Study population inclusion and exclusion 
criteria. FH, family history.
therapy. There are at least six other classes of treatment 
available, for second-line and third-line therapies. Present 
treatment guidelines do not give information on which 
subjects will respond best to specific therapies, so deci-
sions about which drug to prescribe are usually based on 
cost, possible side effects and physician preference.1 If we 
understood the patient characteristics that are predictors 
of response, then treatment selection could be better 
informed.2 3 The huge volumes of data found in elec-
tronic health databases may provide a powerful resource 
for the identification of stratified treatment approaches 
in type 2 diabetes.
Using electronic databases is key to collecting evidence 
to inform potential stratification in type 2 diabetes. The 
Clinical Practice Research Datalink (CPRD) is the largest 
validated primary care longitudinal health record database 
in the world,4 making it ideal for analysis of clinical factors 
associated with response to type 2 diabetes medications. 
CPRD currently includes records from general practices 
across the UK, with over 17.1 million patients with usable 
data.5 The database contains information on patients’ 
demographics (age, sex and so on), medical symptoms 
and diagnoses, biochemistry results, prescribing infor-
mation, and lifestyle factors such as smoking and alcohol 
consumption. Using these data we can assess if different 
glucose-lowering drugs have different factors that predict 
response. The longitudinal nature of the CPRD data will 
also allow models of disease progression and time to 
failure of therapy to be developed.
There is currently no established framework for 
reporting protocols for observational studies with 
electronic health data. There are standard and clear 
guidelines for reporting clinical trials and systematic 
reviews including preregistration. CPRD requires consid-
erable coding to produce an analysis-ready data set, and 
there are many opportunities for differences in interpre-
tation of definitions and different ways of extracting core 
data. Researchers have reported the need for greater 
transparency in planning, data quality and reporting 
studies of observational data.6–9 Schuemie et al10 report 
that results from observational studies cannot be repli-
cated and cites two studies using the same database 
over the same period that found different results. The 
Strengthening the Reporting of Observational Studies 
in Epidemiology (STROBE) guidelines are set for obser-
vational studies, which an electronic health data study 
would be classed as; however, these guidelines are not 
entirely applicable to this type of study.11 Recently the 
STROBE guidelines have been extended specifically for 
studies using routinely collected healthcare data in the 
REporting of studies Conducted using Observational 
Routinely collected Data (RECORD) statement.12 We 
therefore have produced this cohort profile to ensure 
transparency of our approach, marking against the 
STROBE/RECORD recommendations where applicable, 
to enable replication of any results (checklist available in 
online supplementary file 1).
cohort descrIPtIon
data set
We requested CPRD data from all patients who had been 
prescribed one of the following diabetes medications: 
metformin, sulfonylurea,  dipeptidyl peptidase-4 (DPP4) 
inhibitor, glucagon-like peptide 1 receptor (GLP1-R) 
agonist, thiazolidinedione or sodium-glucose co-trans-
porter-2 (SGLT2) inhibitor, with drugs identified from 
the products file using British National Formulary (BNF) 
codes for non-insulin diabetes therapies and identifying 
further matches by searching both generic and trade 
names for these drugs. We excluded medications that 
were not recommended by the National Institute for 
Heath and Care Excellence from our final data set (ie, 
guar gum). Data were extracted on 8 August 2016 and 
contained records from 313 485 patients from up-to-stan-
dard practices. Three authors (LRR, BMS, MNW) 
extracted the data using different software (R V.3.0.2, 
Stata V.13 and Unix shell scripts and SQL). The final data 
sets and extracted values were compared to minimise 
errors in the data extraction process. If there were differ-
ences, the extraction coding was examined for errors or 
omissions.
Inclusion/exclusion criteria
The purpose of the data extraction was to identify all 
patients with type 2 diabetes; we therefore wanted to 
remove other forms of diabetes that may still be in the 
data set. The study inclusion and exclusion criteria are 
listed in figure 1, and the flow of patients through the 
extraction process in figure 2. The data set obtained after 
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Figure 2 Flow of patients through initial data 
extraction. HbA1c, glycated haemoglobin; NICE, National 
Institute for Heath and Care Excellence; PCOS, polycystic 
ovary syndrome. 
this extraction process will consist of patients with type 2 
diabetes; information on initial and repeated treatment 
regimens will be available. Summary data are provided 
in (online supplementary file 2). Further refinement 
will be required to extract a usable data set appropriate 
to a study, for example change in glycated haemo-
globin (HbA1c) at 6 months where we will require 
patients to have a period of stable therapy prior to 
starting new medication and have taken new medication 
for a sufficient period of time to have an effect. Patients 
with type 1 diabetes were removed from the data by 
excluding patients with an age at diagnosis <35 years, 
or patients only treated with insulin, patients whose first 
therapy was insulin or patients who were prescribed 
insulin within 1 year of diagnosis. Read codes for type 
1 diabetes were not used as there are known problems 
with coding errors.13 Other forms of diabetes, such as 
steroid-induced, gestational or maturity onset diabetes 
of the young, were excluded using specific medical 
codes. Medical codes for family history or scoring test 
results (entity types 87 and 372, respectively) and with 
the keywords family, FH, screening and prehistory were 
excluded from the inclusion medical codes list. Any 
patients who did not have a diabetes medical code in 
their records were excluded. Patients on oral solutions 
were also excluded as adherence and dose calculations 
for these patients were likely to be different from other 
patients, introducing potential confounding as to why 
those patients were on oral solutions and could have 
different responses/adherence rates.
Patient characteristics
Age at diabetes diagnosis and duration of disease are key 
criteria associated with severity of disease and therefore 
likely to affect response. Date of diabetes diagnosis is not 
clearly defined in CPRD, so we devised a definition based 
on medical codes, prescriptions and HbA1c results.
The date of diabetes diagnosis was defined as the earlier 
of date of first prescription for a non-insulin diabetes 
therapy, first HbA1c result >47.5 mmol/mol (6.5%) or 
first diabetes diagnostic medical code. Diabetes diag-
nostic codes used were as defined in the inclusion medical 
codes list, with entries restricted to diagnosis entries only 
(consultation type 3). If the diagnosis date is within 91 
days of the current registration date, we assume that the 
patient had been diagnosed prior to registration with the 
practice and diagnosis date is therefore unknown. To 
reduce historic date entry errors, we remove the medical 
code date if it matches patient year of birth or is of the 
format 01–01-XXX and the date is pre-first registration 
date. If the medical code date is before the first registra-
tion date and the HbA1c and therapy date is over 2 years 
after the current registration date, we ignore the medical 
code date. Ages at diagnosis and at start of treatment are 
calculated as appropriate given diagnosis, treatment start 
dates and year of birth.
bIomArker, covArIAte And outcome dAtA
data cleaning
To ensure that we had quality control in our data, we 
have set criteria for data cleaning. In the therapy files 
of diabetes prescriptions, any records after the date of 
death and date of data extraction were removed. The 
time period of a patient in the data set was determined 
by transfer in/current registration date, transfer out, date 
of death and date of data extraction. Where possible we 
identified points of data entry errors, such as biomarker 
values outside sensible clinical limits or obvious errors in 
drug quantities. In our data there were 5 259 645 weight 
and 5 188 426 body mass index (BMI) values. Using the 
median of recorded patient height after the age of 18,14 
for any date which had a weight but no BMI recorded we 
calculate BMI (n=43 890), and similarly for BMI but no 
weight value (n=1935). Any instances of data cleaning are 
detailed below; no other imputations were conducted.
blood test results
Blood test results were extracted for use in both deter-
mining patient response to treatment (using HbA1c) and 
as potential predictors of response (lipids, high-density 
lipoprotein cholesterol, low-density lipoprotein choles-
terol, triglycerides) and renal function (creatinine). 
Table 1 lists quality control measures that were applied 
to biomarker data. Limits were defined after consultation 
with clinicians as clinically plausible, including allowing 
for particularly high or low values, for each biomarker. 
Entries outside these limits were considered data entry 
errors and therefore excluded. Conversions between 
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Table 1 Biomarker limits
Biomarker Units Limits Entity Units code (data3)
HbA1c mmol/mol, % (20, 195) mmol/mol
(3.9, 20) %
Excluding 213 0, 1 (%), 61 (%), 97 (mmol/mol)
Weight Kg (40, 350) 13
BMI Kg/m2 (15, 100) 13
HDL cholesterol mmol (0.2, 10) 175 0, 96
LDL cholesterol mmol (0.1, 20) 177 0, 96, 110 142
Triglyceride mmol (0.1, 40) 202 0, 96
Creatinine μmol (20, 2500) 165 0, 96, 142, 138, 99
ALT (0, 200) 155 0, 61, 127, 164, 277
Glucose mmol/L (2.5, 30) 213, 274 0, 61, 96
Entity and data3 are fields in the CPRD data. Unit code 0 refers to missing units.
ALT, alanine aminotransferase; BMI, body mass index; CPRD, Clinical Practice Research Datalink; HbA1c, glycated haemoglobin; HDL, high-
density lipoprotein; LDL, low-density lipoprotein.
different units were carried out using standard formulae 
to ensure all measures were in the same units. Where 
multiple entries on the same day for the same biomarker 
were found, we took the average.
The main outcome of interest in our study was change 
in HbA1c from baseline. A keyword search was done on 
the list of medical codes to identify when tests of HbA1c 
levels were conducted. Two researchers (BMS and SH) 
carried this out independently and compared results. 
Data were extracted from the test results file matching 
the HbA1c medcodes. Entries with entity 213, iden-
tifying glucose, were excluded. Our study will report 
HbA1c in mmol/mol, and all entries that are recorded in 
percentage units are converted to mmol/mol using stan-
dard formula. HbA1c entries prior to 1 January 1990 were 
removed from the data set; HbA1c was not used clinically 
before this, and the dates are more likely to be data entry 
errors than genuine dates.
We extracted all entries with units mmol/mol, 
per cent and missing units. Entries with other units 
were deemed errors. For all missing units we assumed 
that values ≥3.9 and ≤20 were percentage and 
values >20 and ≤195 were mmol/mol. We also assumed 
that percentage values above 20 were misreported mmol/
mol and mmol/mol values <20 were misreported percent-
ages and adjusted the values accordingly.
drug start and stop criteria
To investigate the effects of new therapies, we defined 
periods of stable treatment regimens by identifying 
breaks in medication both of new and existing therapies. 
Defining start, stop and treatment breakpoints was crucial 
for consistency for time periods on treatment across the 
different drugs. For some patients there could be a long 
break between prescriptions of a given drug, and there-
fore clinically this would be considered stopping and 
restarting the drug.
Gaps of >6 months (183 days) were used to indicate stop-
ping a drug. Start dates for a drug were defined if there 
was no other prescription for that drug in the previous 
6 months. Patients must have at least two prescriptions 
for the drug in the 6 months from the first prescription. 
A patient was considered to have stopped taking a drug 
if there was no new prescription of that drug in the 6 
months following the last prescription.
Initial response 6 months and 12 months after commencing 
therapy
An important outcome is initial response to therapy 
measured by change in HbA1c. We extracted the first 
instance of a new therapy with start and stop dates as 
defined earlier. To ensure that the response was due to a 
new therapy, we defined a period of stable therapy as no 
changes in treatment regimen in the 3 months (91 days) 
prior to the first prescription of the new therapy (starting 
or stopping any other diabetes medication), and the end 
of the period as the earliest of either the last prescription 
date or the last prescription date before another diabetes 
medication is started or stopped (a break in treatment 
regimen). Most patients will have a therapy added to 
their existing treatment regimen and will be on poly-
therapy; this is standard treatment protocol for patients 
with type 2 diabetes. The addition or change in therapy 
is because the existing medication regimen has failed. 
Defining a stable period of treatment prior to adding a 
new therapy will ensure that response is attributed to the 
therapy of interest and not confounded by influence due 
to a reaction, addition or subtraction of other diabetes 
medications.
Patients on insulin as one of their other diabetes medi-
cations were excluded from analyses. Patients on DPP4 
inhibitors and thiazolidinedione as monotherapy were 
excluded as these were considered unusual treatment 
regimens. We excluded any therapies starting within 
3 months of the current registration date. This ensured 
that we were not missing any prescriptions that may have 
occurred before registration. We cannot be sure that regis-
tration is the start of their treatment; we may be missing 
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prescriptions due to a break in registration with the prac-
tice or a new patient at the practice who has previously 
been on the treatment. Patients who had a duration of 
diabetes of less than 1 year are excluded from analyses; 
their behaviour during this first year is expected to be 
different from those with established diabetes. Those on 
thiazolidinedione or gliptin as monotherapy were also 
excluded.
Baseline HbA1c was taken as the closest value to the 
first prescription date of a particular therapy between 6 
months prior and +7 days of that date. Longer time periods 
showed changes in the biomarker values. Six-month and 
12-month responses were the closest HbA1c±3 months 
(91 days) of either 6 months or 12 months after the first 
prescription date for that drug. A 3-month window was 
chosen as we would see an effect on HbA1c after 3 months, 
and the effect at 6 and 12 months would still be seen in 
the 3 months after the 6-month and 12-month points. 
If there was a change in treatment regimen (starting or 
stopping another diabetes medication) between 6 and 12 
months, we did not extract HbA1c values past the date of 
treatment regimen change. This was to ensure that any 
change in HbA1c was due to the therapy of interest and 
not to other changes in glucose-lowering therapies.
Our ±3 months’ allowance for HbA1c response means 
that potentially we would have an HbA1c response from 
patients after 3 months and 9 months for 6-month and 
12-month responses, respectively. We therefore also 
included time on therapy for 6-month response as at least 
3 months on therapy and for 12-month response at least 
9 months (274 days) on therapy. Where the patient was 
on therapy for less than 6 or 12 months, their response 
HbA1c values were taken between 3 months from the start 
of therapy and 3 months after their last prescription or 
up to a change in treatment regimen, whichever is the 
earlier.
Baseline, 6-month and 12-month measures for other 
biomarkers as listed in table 1 were extracted using the 
same process as for HbA1c.
Adherence (medical possession ratio) and dose
The medication possession ratio (MPR) is used to 
assess adherence to medication.15 MPR is reported as a 
percentage and defined as the amount of medication the 
patient has available to them given the amount of time 
it is prescribed for. MPR is based on issued prescriptions 
only; no encashment data are available. Dose is a weighted 
average of prescribed doses over the time period of 
interest. To obtain MPR and dose, we first calculate the 
number of days of tablets for each prescription. MPR and 
dose are not calculated for GLP1 or insulin drugs as they 
are dispensed in pens and injections, and therefore daily 
dose is more difficult to determine.
Some data cleaning is required prior to calculating 
MPR or dose. The number of days of available tablets can 
be calculated using either the number of days field, or by 
dividing the daily dose by total quantity prescribed. Missing 
values can be calculated using any two of the three values. 
Daily dose is defined as the number of tablets taken each 
day. Daily dose is sometimes recorded as milligram rather 
than dose. Where dosage is recorded as 40, 80, 160 or 240 
and the product name contains 80 mg, we convert to a 
number of tablets per day (daily dose). Similarly for daily 
doses of 500, 1000, 1500 and 2000 where the product 
name contains 500 mg, the daily dose is calculated. Total 
quantities of treatment prescribed over 365 (0.1% of 
33 671 394 prescriptions) were assumed to be data entry 
errors and changed to 0 (missing). Quantities of 556 for 
metformin prescriptions are also considered data entry 
errors and corrected to 56. For multiple prescriptions of 
the same drug class on the same day, we took the average 
of the number of days, quantity and dosage.
MPR and dose are calculated only where we had an unin-
terrupted stable treatment period of at least 12 months. 
The time period for MPR was drug start (first prescrip-
tion) to the date of the first prescription after 365 days on 
the drug. The adherence measurement was the number 
of days of available tablets divided by the number of days 
between the start of treatment and the first prescription 
after 365 days, expressed as a percentage.
The daily dose was recorded as 0 in 30% of the 
33 671 394 diabetes prescription records. These were 
often initial prescriptions where patients’ dosage instruc-
tions may be titrated. The number of days of tablets cannot 
be calculated without a daily dose. Where this occurred, 
we removed the prescription from the adherence calcu-
lation, and the time between the start of the prescription 
with zero daily dose and the next was removed from the 
denominator. At least three prescriptions with non-zero 
daily doses were required to calculate the adherence. 
This was deemed to be sufficient information to perform 
a calculation of dose. Patients were considered adherent 
to their medication if the adherence value is between 80% 
and 120% (inclusive). Examination of the data shows 
that adherence above 120% is likely caused by unusual 
prescription regimens and incorrect quantities entered.
Similar to the MPR data, the time period for dose calcu-
lations was drug start date to the last prescription before 
the 12-month HbA1c response value. For each prescrip-
tion the percentage of maximum dose was calculated 
by multiplying dosage (drug strength) by the daily dose 
and then dividing by the maximum possible dosage. The 
maximum dose was taken from the BNF. We extracted 
the maximum dose and a weighted mean dose (weighted 
by days of tablets issued) over the time period. As with 
adherence we required at least three non-zero daily dose 
values to calculate dose information.
FIndIngs to dAte
In our model of initial response to medication as measured 
by change in HbA1c, 91 765 patients had information on 
119 785 first instances of therapy (figure 3). Patients can 
contribute to more than one therapy response but not at 
the same time. Table 2 contains baseline information for 
each medication and the change in HbA1c at 6 months 
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Figure 3 Extraction of patients for data set of 6-month 
response to initial treatment with new therapy as measured 
by change in glycated haemoglobin (HbA1c). DPP4, 
dipeptidyl peptidase-4;TZD, thiozolidinedione.
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who had baseline and 6-month HbA1c recorded. Patients 
were required to have been on stable therapy prior to 
start of therapy, and all prescriptions relating to the treat-
ment run at least 91 days after the current General Prac-
titioner surgery registration date. The majority of 
treatment information is on first-line and second-line 
medications (metformin and sulfonylurea), and we find 
the greatest reduction in HbA1c at 6 months on these 
medications. Patients moving on to third-line therapies 
(thiazolidinedione, DPP4 inhibitor and so on) do so later 
in their disease, shown by longer duration of time since 
diagnosis. These patients tend to be heavier with greater 
weight and BMI.
The impact of taking glucose-lowering medications 
intermittently, rather than as prescribed, on HbA1c has 
not been previously studied. We found that low adher-
ence to commonly used glucose-lowering medications, 
as measured by the MPR, was associated with smaller 
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reductions in HbA1c.16 Data in this study were extracted 
in August 2014. The same protocol was used to define 
patients and outcomes as at 6-month response. This 
cohort of patients was required to have response data at 
12 months, as we defined adherence based on at least 12 
months of data. There were 32 634 patients with 38 100 
treatment instances of duration at least 1 year taken 
from CPRD data with Hba1c measured at baseline and 
12 months. Approximately 13% of CPRD patients were 
non-adherent to medication, varying across different 
medications. For baseline-adjusted HbA1c change over 
1 year, non-adherent patients had consistently lower 
HbA1c reductions than adherent patients, with mean and 
95% CIs of −4.4 (−4.7 to −4.0) mmol/mol (−0.40 (−0.43 
to −0.37) %). The results from the CPRD data were repli-
cated in the GoDARTS  (Diabetes Audit and Research 
Tayside) database, a Scottish database of 9400 patients 
with diabetes containing primary care, pharmacy and 
hospital data.
strengths And lImItAtIons
The CPRD is a superb resource reflecting everyday clinical 
practice and is an ideal data set to identify factors associ-
ated with drug response in a common condition like type 2 
diabetes. However, considerable data cleaning is required 
and rules developed to extract non-entered data, like date 
of diabetes diagnosis. The work on response to glucose-low-
ering therapy mainly requires prescription information and 
biochemistry such as HbA1c; both of these are directly down-
loaded, greatly reducing errors and increasing coverage. 
However the potential for errors still exists especially for 
fields that are entered by hand and different individuals 
may use different codes for the same clinical event. This 
means cleaning and manipulation of the data are required, 
and this paper aims to outline our rationale and methods.
The main purpose defining our cohort data selection is 
to ensure transparency and clarity in extracting response 
data on patients with type 2 diabetes in CPRD. We have 
laid out clear guidelines for extracting and refining 
data, as illustrated in figures 1–2. To ensure within-study 
quality of data extraction, we have minimised errors due 
to coding by using multiple researchers to extract data 
in parallel. This also proved to be a useful exercise in 
different researchers finding additional criteria to add 
to our inclusions and exclusion lists. Our medical and 
therapy codes are added to the (online supplementary 
appendix) for other researchers to use.
Electronic healthcare databases lack the randomisation 
to therapy of a randomised control trial, but real-world 
effectiveness and utilisation of therapies can be assessed.4 
Benefits from the large numbers in the databases include 
the ability to study less common events and the immediate 
availability of long-term follow-up data. Response to ther-
apies can be studied where it is not possible to conduct a 
clinical trial due to cost, ethical considerations or impracti-
calities. However, as this is ‘real life’ data, it may be subject 
to bias and confounding. For example patients are not 
randomly allocated a treatment as in a clinical trial. Popula-
tion heterogeneity, non-linearity of predictors and missing 
data are also a potential problem. For example, a linkage 
with Hospital Episode Statistics (HES) data can provide 
information on some side effects such as hypoglycaemia 
and cardiovascular disease, but this is limited to England 
only. For each study using the data, these issues will need 
to be explored and sensitivity analyses conducted where 
appropriate to explore how robust the models are and 
which models need exclusions or adjustments. Methods 
to deal with unmeasured confounding in non-randomised 
longitudinal studies will be explored,17 such as the prior 
event rate ratio,18 which uses outcomes prior to treatment. 
Although the data are subject to bias, the results from an 
analysis of CPRD data will give a pragmatic analysis of prac-
titioner choices and produce generalisable results; any 
approach to stratification will be applied in ‘real world’ 
care.
Results from the studies using CPRD data will be compared 
with other observational data (GoDARTS database) and trial 
data, now available through online portals such as Clinical 
Data Study Request and Yale University Open Data Access 
YODA. Where possible, models developed in one popula-
tion will be fitted to data from other populations. The direct 
and indirect comparisons across different data sets will help 
to validate any findings.
We have detailed our method for defining and 
extracting initial response to diabetes therapies from 
patients with type 2 diabetes to inform stratification. This 
provides a clear protocol for other researchers to repro-
duce, evaluate and extend work on type 2 diabetics in 
electronic healthcare databases.
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